Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATNF 180 Life Sciences	$0.89 -0.9%	$0.98	$0.66 ▼ $17.75	$5.35M	0.22	664,745 shs	39,402 shs
DARE Dare Bioscience	$2.71 -4.6%	$2.82	$2.11 ▼ $9.19	$23.98M	1.14	375,175 shs	980,838 shs
FNCH Finch Therapeutics Group	$12.75	$13.27	$1.27 ▼ $15.85	$20.48M	1.21	2,135 shs	2,542 shs
RLMD Relmada Therapeutics	$0.64 +0.5%	$0.62	$0.24 ▼ $4.37	$21.08M	0.59	967,685 shs	177,046 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATNF 180 Life Sciences	-0.66%	+12.06%	-8.86%	+1.93%	-55.96%
DARE Dare Bioscience	-8.09%	+18.33%	-6.27%	-2.41%	-15.73%
FNCH Finch Therapeutics Group	0.00%	-1.92%	-7.27%	-1.92%	+706.96%
RLMD Relmada Therapeutics	+0.72%	+3.59%	-9.74%	+116.44%	-83.54%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATNF 180 Life Sciences	0.7793 of 5 stars	0.0	3.0	0.0	2.0	1.7	0.6
DARE Dare Bioscience	1.8288 of 5 stars	3.3	3.0	0.0	3.2	0.0	0.0
FNCH Finch Therapeutics Group	0.7696 of 5 stars	0.0	5.0	0.0	0.0	1.7	0.6
RLMD Relmada Therapeutics	4.7406 of 5 stars	3.1	5.0	4.4	1.9	4.2	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATNF 180 Life Sciences	0.00	N/A	N/A	N/A
DARE Dare Bioscience	2.50	Moderate Buy	$12.00	342.80% Upside
FNCH Finch Therapeutics Group	0.00	N/A	N/A	N/A
RLMD Relmada Therapeutics	2.25	Hold	$5.00	687.40% Upside

Current Analyst Ratings Breakdown

Latest ATNF, DARE, FNCH, and RLMD Analyst Ratings

Date	Company	Brokerage	Action	Rating
7/12/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
6/27/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
6/11/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/24/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/10/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
4/24/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATNF 180 Life Sciences	N/A	N/A	N/A	N/A	$2.91 per share	N/A
DARE Dare Bioscience	$10K	2,398.35	N/A	N/A	($0.69) per share	-3.93
FNCH Finch Therapeutics Group	N/A	N/A	N/A	N/A	$14.25 per share	N/A
RLMD Relmada Therapeutics	N/A	N/A	N/A	N/A	$1.18 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATNF 180 Life Sciences	-$6.17M	N/A	N/A	∞	N/A	N/A	-147.34%	-77.00%	8/11/2025 (Estimated)
DARE Dare Bioscience	-$4.05M	-$0.17	N/A	N/A	N/A	N/A	N/A	-8.14%	8/11/2025 (Estimated)
FNCH Finch Therapeutics Group	-$74.75M	-$8.82	N/A	∞	N/A	N/A	-69.14%	-26.92%	N/A
RLMD Relmada Therapeutics	-$79.98M	-$2.51	N/A	N/A	N/A	N/A	-181.26%	-151.23%	8/6/2025 (Estimated)

Latest ATNF, DARE, FNCH, and RLMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	DARE Dare Bioscience	-$0.55	N/A	N/A	N/A	$0.14 million	N/A
8/6/2025	Q2 2025	RLMD Relmada Therapeutics	-$0.25	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	ATNF 180 Life Sciences	N/A	-$0.67	N/A	-$0.67	N/A	N/A
5/13/2025	Q1 2025	DARE Dare Bioscience	-$0.63	-$0.50	+$0.13	-$0.50	$0.60 million	$0.03 million
5/12/2025	Q1 2025	RLMD Relmada Therapeutics	-$0.31	-$0.58	-$0.27	-$0.58	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATNF 180 Life Sciences	N/A	N/A	N/A	N/A	N/A
DARE Dare Bioscience	N/A	N/A	N/A	N/A	N/A
FNCH Finch Therapeutics Group	N/A	N/A	N/A	N/A	N/A
RLMD Relmada Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATNF 180 Life Sciences	N/A	1.02	1.02
DARE Dare Bioscience	N/A	0.56	0.56
FNCH Finch Therapeutics Group	N/A	3.87	3.87
RLMD Relmada Therapeutics	N/A	5.29	5.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATNF 180 Life Sciences	4.07%
DARE Dare Bioscience	6.70%
FNCH Finch Therapeutics Group	21.77%
RLMD Relmada Therapeutics	45.24%

Insider Ownership

Company	Insider Ownership
ATNF 180 Life Sciences	38.20%
DARE Dare Bioscience	4.00%
FNCH Finch Therapeutics Group	44.90%
RLMD Relmada Therapeutics	20.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATNF 180 Life Sciences	7	6.04 million	3.73 million	No Data
DARE Dare Bioscience	30	8.85 million	8.50 million	Not Optionable
FNCH Finch Therapeutics Group	190	1.61 million	885,000	No Data
RLMD Relmada Therapeutics	10	33.19 million	26.32 million	Optionable

ATNF, DARE, FNCH, and RLMD Headlines

Recent News About These Companies

Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01

July 15 at 8:26 AM | finance.yahoo.com

Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01

July 15 at 8:00 AM | globenewswire.com

Relmada terminates license agreement for troubled phase 3 depression asset

July 11, 2025 | fiercebiotech.comF

DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors

July 9, 2025 | globenewswire.com

Relmada Therapeutics Inc News (RLMD) - Investing.com

July 2, 2025 | investing.com

RLMD Relmada Therapeutics, Inc. - Seeking Alpha

July 2, 2025 | seekingalpha.com

Relmada Therapeutics' Market Cap Drops To US$22m Leaving Insiders With Losses

June 28, 2025 | uk.finance.yahoo.com

Relmada Therapeutics, Inc. (RLMD) - Yahoo Finance

June 26, 2025 | finance.yahoo.com

RLMD - Relmada Therapeutics Inc Executives - Morningstar

June 24, 2025 | morningstar.comM

Relmada Therapeutics Appoints Dr. Raj S. Pruthi as Chief Medical Officer for Urology to Advance NDV-01 Program for Bladder Cancer

June 17, 2025 | quiverquant.comQ

Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology

June 17, 2025 | globenewswire.com

Relmada Therapeutics, Inc. (NASDAQ:RLMD) CFO Purchases $22,000.00 in Stock

May 21, 2025 | insidertrades.com

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2025 Earnings Call Transcript

May 14, 2025 | msn.com

Relmada Therapeutics, Inc. (RLMD) Q1 2025 Earnings Call Transcript

May 12, 2025 | seekingalpha.com

Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025 | globenewswire.com

Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

May 8, 2025 | globenewswire.com

Relmada Therapeutics Presents NDV-01 Data at AUA2025 Conference for High-Risk Non-Muscle Invasive Bladder Cancer

April 28, 2025 | nasdaq.com

Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025

April 28, 2025 | globenewswire.com

Relmada Therapeutics to hold a virtual meeting

April 27, 2025 | markets.businessinsider.com

UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025

April 27, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATNF, DARE, FNCH, and RLMD Company Descriptions

180 Life Sciences NASDAQ:ATNF

$0.89 -0.01 (-0.91%)

As of 12:02 PM Eastern

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.

Dare Bioscience NASDAQ:DARE

$2.71 -0.13 (-4.58%)

As of 12:18 PM Eastern

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

Finch Therapeutics Group NASDAQ:FNCH

$12.75 0.00 (0.00%)

As of 07/14/2025 03:53 PM Eastern

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

Relmada Therapeutics NASDAQ:RLMD

$0.64 +0.00 (+0.47%)

As of 12:05 PM Eastern

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time